

Recent patent applications in antibody-drug conjugates

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
US20130280815A1	Methods for determining the number of drug molecules present in at least one antibody-drug conjugate (ADC) species subpopulation, comprising performing free solution isoelectric focusing on a sample comprising at least one ADC species, measuring the absorbance of the sample at two different wavelengths, comparing absorbance values and determining the number of drug molecules in the ADC species subpopulation based on the comparison.	ProteinSimple (Santa Clara, CA, USA)	Wu J.	4/19/2012	10/24/2013
US8541178B2	Methods to capture, detect, analyze, screen, characterize and quantify antibody-conjugate compounds, including antibody-drug conjugates and their fragments and metabolites by mass spectrometry.	Genentech (S. San Francisco, CA, USA), Kaur S., Saad O., Xu K.	Kaur S., Saad O., Xu K.	5/13/2008	9/24/2013
US8535678B2	A new antibody-drug conjugate comprising an antibody that binds to CD70 and that is conjugated to a cytotoxic agent or an immunosuppressive agent and exerts a cytotoxic or cytostatic effect on a CD70-expressing cancer cell line or a cytotoxic, cytostatic or immunosuppressive effect on a CD70-expressing immune cell.	Seattle Genetics (Bothell, WA, USA), Law C., Wahl A.F., Scholler N., Pestano L.A.	Law C., Wahl A.F., Scholler N., Pestano L.A.	2/20/2003	9/17/2013
US8535677B2	An antibody or other affinity reagent comprising an affibody, nanobody or unibody capable of immunospecifically binding with OGTA001.	Oxford BioTherapeutics (Oxon, UK), Rohlf C., Terrett J.A.	Rohlf C., Terrett J.A.	6/6/2006	9/17/2013
US20130224228A1	Combination therapy with radiolabeled antibodies and drug-conjugated antibodies; may be of use for treatment of cancers for which standard therapies are not effective, such as pancreatic cancer.	Igenica (Burlingame, CA, USA)	Jackson D.Y., Ha E.	12/5/2011	8/29/2013
US20130209496A1	Treating cancer and treating, killing and/or inhibiting the proliferation of tumor cells in a subject, comprising administering an auristatin-based antibody drug conjugate and an inhibitor of the phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway.	Seattle Genetics (Bothell, WA, USA), Lewis T.S., Law C., McEarchern J.A.	Lewis T.S., Law C., McEarchern J.A.	10/22/2010	8/15/2013
US20130171095A1	A composition comprising a heterodimer protein comprising a first monomer comprising (i) first variant heavy chain constant region and (ii) first fusion partner, and a second monomer comprising (i) second variant heavy chain constant region and (ii) second fusion partner, where the isoelectric points of the first and second variant heavy chain constant regions are at least 0.5 logs apart.	Xencor (Monrovia, CA, USA)	Bernett M.J., Moore G.L., Desjarlais J., Rashid R.	10/10/2011	7/4/2013
US20130209356A1	Treating an autoimmune disorder, comprising administering a therapeutic composition comprising a carrier and at least one antibody to a B-cell antigen.	Immunomedics (Morris Plains, NJ, USA)	Govindan S.V., Goldenberg D.M.	6/14/2002	8/15/2013
US8470329B2	Treating Hodgkin lymphoma in a subject comprising administering to a subject (i) gemcitabine and an antibody-drug conjugate compound, or (ii) a chemotherapeutic regimen comprising doxorubicin, bleomycin, vinblastine and dacarbazine and an antibody-drug conjugate compound, where the antibody-drug conjugate is an anti-CD30 antibody conjugated to an auristatin compound.	Seattle Genetics (Bothell, WA, USA), Oflazoglu E., Sievers E., Gerber H.-P.	Oflazoglu E., Sievers E., Gerber H.-P.	10/12/2007	6/25/2013
US8435529B2	Treating cancer comprising administering an anti-Trop-2 antibody or its antigen-binding fragment conjugated to a first therapeutic agent, and an anti-pancreatic cancer mucin antibody or its antigen-binding fragment conjugated to a second therapeutic agent.	Immunomedics (Morris Plains, NJ, USA), Govindan S.V., Goldenberg D.M.	Govindan S.V., Goldenberg D.M.	6/14/2002	5/7/2013
US8398982B2	Inhibiting growth of a colon or rectum cancer cell that expresses a protein comprising fully defined 411 amino acids, comprising contacting the cell with an antibody-drug conjugate comprising a growth-inhibitory agent or a cytotoxic agent conjugated to a first antibody that binds to the protein, where the binding of the antibody-drug conjugate to the protein causes an inhibition of the growth of the colon or rectum cancer cell.	Genentech (S. San Francisco, CA, USA), Wu T.D., Spencer S.D., Smith V., Polakis P., Frantz G., Dowd P., Zhang Z.	Dowd P., Frantz G., Polakis P., Smith V., Spencer S.D., Wu T.D., Zhang Z.	6/20/2001	3/19/2013

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Reuters (Search Service), 1925 Ballenger Avenue, Suite 400, Alexandria, VA 22314, USA. Tel: 1 (800) 337-9368 (<http://thomsonreuters.com/>).